StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) income statement

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3038% below fair value
$32.59−0.39 (-1.18%)

Close on Nov 20, 2026Market cap $1.90BP/E 10.5Yield –

Harmony Biosciences Holdings, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
75.4%
Operating margin
24.0%
Net margin
18.9%
Return on equity, FY2025
20.8%

Financial strength

Current ratio
3.48
Debt to equity
0.15
Debt to assets
11.2%
Cash to current liabilities
234.9%

Valuation

P/E ratio
10.5
Price to sales
1.98
Price to book
1.90
Dividend yield
–

See a number that looks wrong?